Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Portfolio Pulse from
Lucid Diagnostics' ESOGUARD BE-1 study on EsoGuard® Esophageal Precancer Testing has been accepted for publication, completing their clinical evidence package for Medicare coverage submission.
November 07, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics' ESOGUARD BE-1 study has been accepted for publication, enhancing the credibility of their EsoGuard® test and completing the evidence package for Medicare coverage submission.
The acceptance of the ESOGUARD BE-1 study for publication in a peer-reviewed journal enhances the credibility of Lucid Diagnostics' EsoGuard® test. This is a significant step as it completes the clinical evidence package required for Medicare coverage submission, potentially increasing the test's market adoption and revenue.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Lucid Diagnostics, a subsidiary of PAVmed Inc., has had its ESOGUARD BE-1 study accepted for publication, which is a positive development for PAVmed as it supports the subsidiary's product credibility and market potential.
As Lucid Diagnostics is a subsidiary of PAVmed Inc., the acceptance of the ESOGUARD BE-1 study for publication positively impacts PAVmed by enhancing the credibility and market potential of its subsidiary's product, which could lead to increased revenue and valuation for PAVmed.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 70